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In Brief
Following a severe primary infection, the risk of developing pneumonia increases due to acquired immune defects collectively known as sepsis-induced immunosuppression. Roquilly et al. show that resolution of the primary infection changed the local environment, leading to the development of DCs and macrophages that are functionally impaired in terms of T cell activation, and instead exhibit tolerogenic properties that contribute to immune suppression.
SUMMARY
Lung infections cause prolonged immune alterations and elevated susceptibility to secondary pneumonia. We found that, after resolution of primary viral or bacterial pneumonia, dendritic cells (DC), and macrophages exhibited poor antigenpresentation capacity and secretion of immunogenic cytokines. Development of these ''paralyzed'' DCs and macrophages depended on the immunosuppressive microenvironment established upon resolution of primary infection, which involved regulatory T (Treg) cells and the cytokine TGF-b. Paralyzed DCs secreted TGF-b and induced local Treg cell accumulation. They also expressed lower amounts of IRF4, a transcription factor associated with increased antigen-presentation capacity, and higher amounts of Blimp1, a transcription factor associated with tolerogenic functions, than DCs present during primary infection. Blimp1 expression in DC of humans suffering sepsis or trauma correlated with severity and complicated outcomes. Our findings describe mechanisms underlying sepsis-and traumainduced immunosuppression, reveal prognostic markers of susceptibility to secondary infections and identify potential targets for therapeutic intervention.
INTRODUCTION
Pneumonia is the leading cause of death from infectious disease (Mizgerd, 2006) . The risk of developing pneumonia increases following severe primary infections and reaches 30%-50% for critically ill patients recovering from a first episode of infection (van Vught et al., 2016a) . It is currently accepted that susceptibility to secondary pneumonia increases due to acquired immune defects collectively known as sepsis-induced immunosuppression (Hotchkiss et al., 2013a; Roquilly and Villadangos, 2015) . In-depth understanding of the mechanisms involved is vital to prevent and treat secondary pneumonia in patients recovering from a primary infection.
Healthy lungs are colonized by bacteria whose burden is continuously controlled by mucosal immunity (Charlson et al., 2011) . Infection by pathogenic bacteria disrupts this balance and can induce lung injury through direct damage caused by the pathogen, or through immunopathology elicited by the effector mechanisms of immunity. Therefore, a healthy immune response should maximize the deployment of effector mechanisms against the pathogen while minimizing the damage of self-tissues that might ensue.
As macrophages and dendritic cells (DC) orchestrate immunity and tolerance, we compared their functional properties before, during, and after resolution of pneumonia. Both cell types showed profound alterations-which we summarize as ''paralysis''-in the latter case. Paralysis was caused by excessive release of local mediators of restoration of immune homeostasis. Our findings suggest that DC and macrophage dysfunction is an important contributor to protracted immunosuppression after bacterial or viral primary sepsis and increased susceptibility to secondary pneumonia.
RESULTS

Recovery from Primary Pneumonia Is Followed by Increased Susceptibility to Secondary Infection
Escherichia coli (E. coli) is the second most frequent gram negative bacilli involved in both community-and hospitalacquired pneumonia (Roquilly et al., 2016; van Vught et al., 2016b) . Early recurrence of pneumonia to the same pathogens is observed in up to 20% of critically ill patients cured from primary pneumonia (Chastre et al., 2003) . To mimic in mice this clinical scenario, we induced secondary pneumonia with E. coli in mice cured from a bacterial (E. coli) or a viral (influenza A virus, IAV) primary pneumonia ( Figure 1A ). During primary E. coli pneumonia, pathogen burden and mouse weight loss peaked 1 day after infection and then decreased until by day 7 the mice had cleared the bacterium ( Figure 1B ) and recovered their normal weight ( Figure 1C ). If these mice were re-infected with E. coli 7 to 21 days after the primary infection, they suffered more severe (secondary) pneumonia with increased bacterial burden and weight loss (Figures 1C and 1D) . Similarly, mice infected with E. coli suffered more severe pneumonia if they had previously been infected with, and recovered from primary pneumonia caused by IAV . We exploited this experimental model to characterize potential mechanisms of sepsis-induced (B) Time course of the bacterial load after intra-tracheal instillation of E. coli in naive mice (primary pneumonia) (n = 3 mice per group). (C) Mouse weight loss during primary and secondary E. coli pneumonia realized 7 days after E. coli primary pneumonia (n = 3 mice per group).
(D) Enumeration of colony-forming units (CFU) per milliliter of bronchoalveolar lavage (CFU/mL) analyzed one day after secondary E. coli pneumonia (75 mL of DH5a intra-tracheal, OD 600 = 0.6) induced at the indicated times after E. coli primary pneumonia (n = 6 mice per group).
(E) Enumeration of CFU per milliliter of bronchoalveolar lavage analyzed one day after secondary E. coli pneumonia (75 mL of DH5a intra-tracheal) induced 7 days after influenza A virus (IAV) primary pneumonia (n = 5 mice per group).
(F and G) At the indicated times after (F) E. coli or (G) IAV primary pneumonia, Cell Trace Violet-labeled OT-II cells (iv) and OVA-coated E. coli (intra-tracheal) were injected concomitantly in WT mice. OT-II proliferation was assessed 60 hr later in the mediastinal lymph node (n = 6-7 mice per group, except day 14 and day 21 n = 3). *p < 0.05, **p < 0.01, #p < 0.01 versus all infected groups, one-way ANOVA. Graphs represent mean ± SD and are pooled data from 2-3 independent experiments.
immunosuppression (Hotchkiss et al., 2013a; Roquilly and Villadangos, 2015; van Vught et al., 2016a) .
Defective CD4 T Cell Priming Following Recovery from Primary Pneumonia
We first assessed T cell priming in mice that recovered from bacterial pneumonia by re-infecting them 7-21 days after the primary infection with E. coli associated with the model antigen, ovalbumin (OVA). The mice also received MHC II-restricted, OVA-specific OT-II cells, which proliferated in the mediastinal lymph nodes (LN) in response to local presentation of OVA. We observed a severe reduction in OT-II proliferation during secondary pneumonia compared to that observed in mice that received E. coli-OVA as a primary infection ( Figure 1F ). Similar results were obtained in mice where primary pneumonia was caused by IAV ( Figure 1G ).
TGF-b Is Involved in Pneumonia-Induced Immunosuppression via Treg Cell Induction
Tumor growth factor (TGF)-b is critical for tissue healing after injury and is immunosuppressive (Akhurst and Hata, 2012) . To test whether TGF-b released within lung tissue during or after primary pneumonia induced immunosuppression, we neutralized it with a mAb injected 3 and 6 days after initiation of primary pneumonia. This treatment did not affect bacterial burden or weight changes during primary infection (Figures S1A-S1D), but it caused reduced bacterial burden and increased OT-II cell priming during secondary pneumonia (Figures 2A and 2B ). This indicated a role for TGF-b on the induction of immunosuppression after recovery from primary infection. TGF-b induces differentiation of naive CD4 T cells into FoxP3 + T regulatory (Treg) cells (Chen et al., 2003) . We found a higher proportion of lung Treg cells after recovery from primary bacterial or IAV pneumonia (Figures S2A and S2B) , and also in the lungs of mice suffering secondary pneumonia ( Figure 2C ), than in mice uninfected or suffering primary pneumonia. Treatment with anti-TGF-b reduced Treg cells accumulation ( Figure 2D ), so we investigated the role of Treg cells in susceptibility to secondary infection. We infected transgenic mice expressing the diphtheria toxin receptor (DTR) in FoxP3 + cells (DEREG mice), where we could deplete Treg cells after initiation of primary or secondary pneumonia ( Figure S2C ). Depletion of Treg cells during the resolution of primary pneumonia (from days 4 to 7 post primary infection) did not alter the course of this infection (Figures S2D and S2E) , but restored the effectiveness of bacterial clearance, and enhanced CD4 + T cell priming, during secondary pneumonia ( Figures 2E and 2F ). Thus, TGF-b in the lungs of mice that recovered from primary pneumonia induced Treg cell accumulation during secondary pneumonia, which contributed to immunosuppression.
Macrophages and DC Produce TGF-b in Infection-Cured Mice Next we sought to identify the cells that produced TGF-b in the lungs of mice cured from primary infection. Expression of TGF-b mRNA did not vary in non-hematopoietic cells (CD45 neg ) in infection-cured mice ( Figure S2H ), suggesting the cells responsible were hematopoietic. Macrophages and DC produce and activate TGF-b, inducing Treg cell formation (Chen et al., 2003) , and the Treg cells that accumulated in infection-cured mice were neuropilin neg ( Figure S2I ), indicating they were peripherally induced rather than thymus-derived, natural Treg (Weiss et al., 2012) . Indeed, we observed increased TGF-b mRNA expression in lung DC of mice recovered from primary pneumonia ( Figure 3A ), although expression of RNA for TGF-b activators remained unchanged ( Figure S2J ). Production of TGF-b protein, as assessed by the membrane expression of its inactive precursor Latency-Associated Peptide (LAP) (Annes et al., 2003) , was increased in CD11b + DC of mice cured from primary pneumonia compared to DC of naive mice ( Figure 3B ). This correlated with the ability of these DC to induce Treg cells in vitro ( Figure 3C ). We used CD11c-DTR transgenic mice, where we could deplete both macrophages and DC (Figures S3A and S3B) , to test their role in Treg cell induction. Their depletion did not affect the number of lung CD4 T cells ( Figure S3C ), but it reduced the number of Treg cells in mice recovered from primary pneumonia ( Figure 3D ) or suffering secondary pneumonia (Figure 3E) . This reduction was reversed with anti-TGF-b treatment ( Figure 3D , red dots). Altogether, these results indicate that DC and macrophages of mice that recovered from primary pneumonia produce TGF-b and promote Treg cell differentiation.
Macrophages and DC Newly Produced after Severe Primary Pneumonia Are Paralyzed DC and macrophages become activated, increase in numbers ( Figures S3D and S3E ) and elicit protective immunity (Figures S3F and S3G) against primary E. coli infection, yet as shown above these cells appear critical in the induction of tolerance to secondary infection. We therefore sought to compare further the function and phenotype of these two cell types before, during, and after primary pneumonia. Capture and presentation of pathogen antigens via MHC-II is a hallmark property of DC and macrophages (Guilliams et al., 2013; Segura and Villadangos, 2009) , and though their numbers during primary and secondary pneumonia were comparable ( Figure S4A ), MHC II-mediated T cell priming was defective in mice suffering secondary pneumonia for at least 21 days after recovery from primary infection ( Figures 1E and 1F ). Both macrophages and DC of mice that recovered from primary pneumonia showed defective antigen-presentation capacity in vitro (Figure 4A) . We have shown that primary pneumonia causes systemic activation of lung DCs ( Figure S4B ), and since mature DCs cannot present newly encountered antigens (Vega-Ramos et al., 2014; Wilson et al., 2006) , persistent DC maturation might explain the lack of antigen presentation by DC in mice that recovered from primary pneumonia. However, neither DCs nor macrophages exhibited signs of activation (high CD86 expression) at that stage ( Figure S4B ). Moreover, measurements of BrDU incorporation showed the rate of macrophages and DC renewal in mice recovered from primary pneumonia was comparable to that in non-infected mice ( Figure 4B ). This suggested that, as the mice recovered from primary pneumonia, activated DC and macrophages were replaced by ''immature'' cells that were defective at detecting and/or presenting antigen from a secondarily infecting pathogen. Both DC and macrophages increased CD86 expression at the onset of secondary infection with E. coli in the lungs ( Figures S4C and S4D ), demonstrating they were still responsive to pathogens. Targeting antigen to a surface DC receptor can overcome defects in antigen presentation , and we observed effective OT-II priming in mice recovered from primary pneumonia if they received OVA conjugated to a mAb that recognizes the DC receptor, DEC-205 ( Figure 4C ). Furthermore, OT-II priming occurred in infection-cured CD11c-OVA transgenic mice challenged with a secondary E. coli infection, in which macrophages and DC constitutively express and present OVA ( Figure 4D ). Therefore, OT-II activation and induction of proliferation can occur in mice suffering a secondary infection if the T cells encounter their cognate MHC-peptide complex on the surface of CD11c high cells (DC). This series of experiments demonstrate that DC and macrophages, which continually turn over in the lungs (Kamath et al., 2002) , develop with impaired capacity to capture, process, and/ or generate MHC-II-peptide complexes for 21 days or more after recovery from primary pneumonia. (A) WT mice were treated with anti-TGF-b or isotype control monoclonal antibody after primary (1ary) E. coli pneumonia (44 mg i.p. at day+3 and day+6) then injected with E. coli at day+7 (2ary pneumonia). The number of CFU per milliliter of bronchoalveolar lavage (BAL) was assessed 18 hr later (n R 5 mice per group). (B) WT mice were treated with anti-TGF-b or isotype control monoclonal antibody after primary (1ary) E. coli pneumonia (44 mg i.p. at day+3 and day+6), and subsequently injected (day+7) with OVA-coated E. coli (intra-tracheal) and Cell Trace Violet labeled OT-II (secondary, 2ary pneumonia). OT-II proliferation was assessed 60 hr later in the mediastinal lymph node (n = 5-6 mice per group). (C) Frequency and number of lung FoxP3 + CD4 T cells in WT mice that were uninfected, or infected with E. coli to elicit primary pneumonia (1ary PN, black dots), or following secondary E. coli pneumonia (2ary PN, gray dots) elicited 7 days following (I) E. coli or (II) IAV (each dot represents an independent biological replicate).
(D) Number and frequency of lung FoxP3 + CD4 T cells in WT mice treated with anti-TGFb or isotype control monoclonal antibody after primary pneumonia (44 mg ip. at day +3 and day +6), and subsequently challenged (day+7) with secondary pneumonia (n = 5-6 mice per group).
(E) Number of CFU per milliliter of bronchoalveolar lavage (BAL) during primary (1ary) or secondary (2ary) pneumonia in WT or DT-treated DEREG mice (DT 0.1 mg ip. day+4 and day+6 after 1ary pneumonia) (n = 3-4 mice per group). (F) 7 days E. coli primary pneumonia, WT, or DT-treated DEREG mice (DT 0.1 mg ip. day+4 and day+6 after 1ary pneumonia) were subsequently injected with OVA-coated E. coli (intra-tracheal) and Cell Trace Violet labeled OT-II (secondary, 2ary pneumonia). OT-II proliferation was assessed 60 hr later in the mediastinal lymph node (n = 5-6 mice per group). *p < 0.05, **p < 0.01, # p < 0.05 versus all others. Graphs represent mean ± SD and are a compilation of 2-3 independent experiments. See also Figures S1 and S2A-S2G.
Cytokine Production by Macrophages and DC during Secondary Pneumonia
Production of immunogenic cytokines by macrophages and DC is as, if not more, critical for the control of infection than antigen presentation, as these cytokines regulate both innate and T celldependent immunity (Marchingo et al., 2014) . We identified CD103 + DC, alveolar macrophages, and CD11b + DC as the main sources of interleukin (IL)-12, tumor necrosis factor (TNF)-a and IL-6, respectively, during E. coli primary pneumonia (Figure S5A) . Production of these cytokines during secondary pulmonary infection with E. coli was significantly impaired for up to 30 days in mice recovered from primary E. coli or IAV pneumonia ( Figures 4E and 4F ). This defect was apparent even if the dose of E. coli causing secondary pneumonia was increased 3.3 times ( Figure S5B ), or if the bacterium causing the secondary pneumonia was different to the one that caused the primary one (e.g., Staphylococcus aureus or Pseudomonas aeruginosa, Figure S5C ). IL-12 is required to elicit interferon (IFN)-g production by NK cells ( Figure S5D ), a cytokine that in turn plays a critical role in the resolution of bacteria-induced pneumonia . Treatment of mice with IL-12 during secondary pneumonia enhanced bacterial clearance ( Figure 4G ), and restored IFN-g production by NK cells ( Figure S5E ). These results show that defective immunogenic cytokine production by macrophages and DC plays a central role in the increased susceptibility of infected-cured mice to secondary pneumonia.
Altered Transcriptional Programming in DC following Primary Pneumonia
Next we compared the expression of phenotypic markers and immunoregulatory factors in DC before and after pneumonia. We found no significant changes in the expression of characteristic surface markers of DC (CD11c, CD24, MHC-II, DEC205, CD103, and CD11b) and macrophages (F4/80, CD64, Ly6G, CD11c, CD11b) ( Figures S6A and S6B ). In contrast, the amounts of key transcription factors involved in the control of (legend continued on next page) immunogenic versus tolerogenic functions of DCs were significantly altered (Steinman et al., 2003) ( Figure 4H ). Specifically, the amount of IRF4, which promotes antigen presentation to CD4 T cells (Vander Lugt et al., 2014) , was lower in CD11b + DC and in CD103 + DC after clearance of the infection ( Figure 4H ).
Conversely, expression of the transcription factor Blimp1, which induces tolerogenic functions in DC (Kim et al., 2011) , was increased ( Figure 4H ). Expression of two other transcription factors involved in DC development and whose expression in DC is critical for immune response to pathogens (Belz and Nutt, 2012; Hambleton et al., 2011) , ID2 and IRF8, remained unchanged (Figure 4H) . Expression of these four transcription factors did not change in macrophages ( Figure S6C ). Thus, although neither the rate of DC turn over ( Figure 4B ) nor the expression of characteristic surface markers of DC subtypes changed substantially after resolution of primary pneumonia, the expression of transcription factors that regulate DC function did.
DC Programming Is Locally Mediated by Secondary Inflammatory Signals
To examine whether the signals responsible for reprogramming of DC after pneumonia acted systemically, we assessed the phenotype and function of splenic DC 7 days following primary pneumonia. Neither the expression of transcription factors (Figure 4I ), nor capacity for T cell priming and cytokine production of these cells were altered 7 days after E. coli pneumonia ( Figures  4J and 4K) . Therefore, signals that induce altered DC functions after recovery from primary pneumonia only act locally on cells that undergo terminal differentiation in the same tissues that suffered the infection. Next we addressed whether such signals consisted of pathogen-derived products that lingered at the infection site (Cegelski et al., 2008) , or of endogenous mediators produced by the affected tissues (Vega-Ramos et al., 2014). We generated mixed-bone marrow chimeras where wild-type (WT) mice received a 1:1 ratio of bone marrow from WT (CD45.1 Figure S7A ). In this setting, Tlr9
À/À cells cannot recognize the pathogen-associated molecular pattern mimic CpG, but can receive signals from secondary mediators released by WT cells responding to CpG (Vega-Ramos et al., 2014) . Intra-tracheal administration of CpG induced a lung inflammatory response that caused lung DC and macrophage activation, followed by a 7-day long recovery phase in which the activated cells were replaced by immature cells (Figures S7B and S7C) , reproducing the time course of the recovery from E. coli or IAV infection. At day 7 post-CpG treatment, we challenged the chimeric animals with E. coli and measured cytokine production by WT and Tlr9 À/À DC or macrophages, finding both groups of cells displayed reduced production of IL-12 and IL-6 compared to their counterparts from naive mice ( Figure 5A ). This result implied that the functional alterations observed in DC and macrophages following recovery from pneumonia were induced not by direct encounter of pathogen products but by secondary mediators of inflammation.
TGF-b Contributes to Program Macrophages and DC after Resolution of Primary Pneumonia
We reasoned that since TGF-b influences acquisition of functional properties during DC development (Sathe et al., 2011) , its production in mice recovered from primary infection might contribute to the local imprinting of DC toward tolerance. Neutralization of TGF-b with a blocking mAb injected during, or after resolution of, primary pneumonia reduced the defects in DC cytokine production during secondary infection ( Figures  5B and 5C ). To explore further the role of TGF-b signaling on DC modulation, we used Tgfbr2 fl/fl Cd11c cre mice, which lack expression of TGF-b receptor selectively in DC and macrophages. These mice spontaneously succumb to inflammatory disease (Ramalingam et al., 2012) , so we generated mixed bone marrow chimeras where WT mice were reconstituted with a 1:3 mix of Tgfbr2 fl/fl Cd11c cre and WT bone marrow.
Seven days after E. coli infection, the proportion of TGF-bRdeficient CD11c cells (CD45.2 + cells) in the lungs of these mice was significantly lower than in uninfected chimeras (Figure 5D ), confirming the role of TGF-b in macrophage and DC renewal after infection.
In order to investigate the role of TGF-b signaling in macrophages and DC on their ability to prime CD4 T cells, we generated mixed bone marrow chimeras where WT mice were reconstituted with a 1:3 mix of Tgfbr2 fl/fl Cd11c cre and H2 À/À (MHC-II-deficient) bone marrow. In these chimeric mice, only the cells derived from the Tgfbr2 fl/fl Cd11c cre bone marrow are able to present antigen to, and prime, CD4 T cells. TGF-bR-deficient CD11c cells (C) Cell Trace Violet-labeled OT-II cells (iv.) and anti-DEC205-OVA (intra-tracheal) were delivered to WT mice that were naive (uninfected) or infected 7 days prior with E. coli (infection-cured). OT-II proliferation was assessed 60 hr later in the mediastinal lymph node (n = 5 mice per group). (D) Cell Trace Violet-labeled OT-II cells (i.v.) and E. coli (intra-tracheal) were administered to CD11c-OVA mice that were naive (1ary pneumonia) or E. coli infection-cured (2ary pneumonia). OT-II proliferation was assessed 60 hr later in the mediastinal lymph node (n = 5 mice per group). (E and F) Frequencies of IL-12 + CD103 DC, TNF-a + alveolar macrophages and IL6 + CD11b DC during primary (1ary) E. coli pneumonia (75 mL of DH5a intratracheal, OD 600 = 0.6) or secondary (2ary) E. coli pneumonia realized at the indicated time point after (E) E. coli or (F) Influenza A Virus (IAV) 1ary pneumonia (n > 8 mice at day 7, n = 2-3 at day 14, 21, 30, and 45).
(G) Enumeration of CFU from bronchoalveolar lavages 16 hr following intra-tracheal injection of E. coli (75 mL of DH5a intra-tracheal, OD 600 = 0.6) in either naive mice (primary, 1ary pneumonia), or infection-cured (2ary pneumonia) with or without IL-12 treatment (100 ng i.p.) concurrent with induction of 2ary pneumonia (n = 4-6 independent mice). (legend continued on next page) retained the ability to elicit effective priming of OT-II cells during secondary pneumonia in vivo ( Figure 5E ). Finally, we examined whether reduced cytokine production by DC and macrophages during secondary pneumonia was also caused by TGF-b recognition by the cells themselves. This did not appear to be the case because in WT:Tgfbr2 fl/fl Cd11c cre mixed bone marrow chimeras, both the WT and the TGF-bRdeficient cells were impaired during secondary pneumonia (Figure 5F ). Because neutralization of TGF-b rescued IL-12 and IL-6 production by DC and macrophages ( Figures 5B and 5C ), this suggested that TGF-b acted through an indirect mechanism to impair cytokine production by the two cell types. Treg cells are known to inhibit DC functions (Onishi et al., 2008) and depletion of Treg cells during the resolution of primary pneumonia enhanced IL-12 and IL-6 production by macrophages and DC during secondary infection ( Figure 5G ). Together, our results indicate a pivotal role for TGF-b in the induction of DC and macrophages with reduced immunogenic function. It acts directly on developing cells, and indirectly via Treg cells.
Expression of Blimp1 in CD1c + DC and Numbers of Treg Cells in Human Patients Suffering Systemic Inflammatory Response Syndrome
Finally, we addressed whether the conclusions of our studies in mouse models of infection could be extrapolated to the human system. First, we analyzed PBMC from a prospective cohort of septic patients presenting with E. coli secondary infection (IBIS sepsis, n = 5 [ Table S1 ]). Human CD1c DC, the circulating equivalent of murine CD11b DC (Guilliams et al., 2014) , expressed high level of the transcription factor Blimp1 in these patients as compared to matched uninfected donors ( Figure 6A ), paralleling the result observed in mice. Also reproducing what we observed in infected-cured mice ( Figure 4H ), CD141 DC (the human equivalent of murine CD103 + DC) did not show increased Blimp1 expression in these patients ( Figure 6A ).
Since we found in mice that the reprogramming of DC is not pathogen-driven but induced by secondary mediators of inflammation, we reasoned that Blimp1 + CD1c DC might also be observed in patients suffering aseptic SIRS, such as severe trauma patients, who are highly susceptible to secondary pneumonia (Asehnoune et al., 2012) . We thus examined circulating DC from patients suffering from trauma-induced severe inflammation (IBIS cohorts 1 and 2, n-32 and n-29 respectively Table  S2 ). We have previously shown that circulating DC from these patients have lost their ability to produce TNF-a, IL-6, and IL-12 upon in vitro stimulation (Roquilly et al., 2013) , reproducing a hallmark of mouse paralyzed DC ( Figures 4E and 4F ). Blimp1 expression was also increased in circulating CD1c DC collected from these trauma patients as compared to matched healthy controls ( Figure 6B ). The level of expression of Blimp1 in circulating CD1c DC increased with the severity of the trauma (Figure 6C) and correlated with the duration of mechanical ventilation, a surrogate marker of complicated outcome ( Figure 6D ). We also found an increase in the number and frequency of circulating Treg cells in trauma patients ( Figure 6E ), which again correlated with trauma severity ( Figure 6F ).
DISCUSSION
The effector mechanisms deployed by the immune system to fight pathogens can cause tissue damage and have to be tightly controlled to prevent self-harm. Here we have described a network of regulatory mechanisms that dampen the immune response locally in response to lung infection. It involves multiple cell types and cytokines, with macrophages and DC playing a pivotal role. Importantly, after clearance of the infection the immunosuppression induced by these mechanisms does not restore immune homeostasis to the situation that preceded the infection. It persists locally for weeks after resolution of the infection, increasing the susceptibility to secondary infections. DCs respond quickly to pathogen encounter by presenting antigens to induce T cell responses and releasing cytokines that promote both innate and adaptive immunity (Banchereau and Steinman, 1998) . During this response they undergo a process of ''maturation'' that involves multiple genetic, phenotypic, and functional changes (Landmann et al., 2001; Wilson et al., 2006) . DC have a short half-life, both in the steady-state and after infection (Kamath et al., 2002) , being continually replaced by new DC derived from precursors immigrated from the bone marrow (Geissmann et al., 2010) . Final DC differentiation occurs in peripheral tissues under the influence of local cytokines that modulate the responsiveness and functional properties of the newly produced DC (Amit et al., 2016) . Our results show that the DC that develop in the lung after resolution of pneumonia have diminished capacity to present antigens and to secrete immunostimulatory cytokines, which makes them less capable of initiating adaptive and innate immunity against a secondary bacterial infection. In addition, they produce higher levels of TGF-b, which promotes accumulation of Treg cells. We showed that the signals that promote the differentiation of DC to this paralyzed state are not directly associated with the pathogen that caused the primary infection; they are mediated by secondary cytokines acting locally. TGF-b plays a prominent role in the differentiation of paralyzed DC, although our results do not discard were injected in naive (primary, 1ary pneumonia) or E-coli infection-cured (secondary, 2ary pneumonia) chimeras. 60 hr later, the proliferation of OT-II was assessed in the mediastinal lymph nodes (n = 5-6 mice per group). (G) Frequency of IL12 + alveolar macrophages, IL12 + CD103 DC and of IL6 + CD11b DC during primary (1ary) or secondary (2ary) pneumonia in wild-type (WT) or DT-treated DEREG mice (DT 0.1 mg i.p. day+4 and day+6 after 1ary pneumonia) (n > 6 mice per group). *p < 0.05, ***p < 0.001, #p < 0.05 versus all others. Graphs represent mean ± SD and display data pooled from 2-3 independent experiments. See also Figures S7. (E) Number and frequency of circulating CD4 Treg in brain-injured patients suffering from trauma-induced systemic inflammation. Blood samples were collected 1 and 7 days after the trauma (n = 27 severe trauma patients).
(F) Correlation between the accumulation of Treg (Delta = number at day 7 -number at day 1) and trauma severity in brain-injured patients. Glasgow Coma Scale rates the severity of the brain-injury from 15 (minor injury) down to 3 (major injury). *p < 0.05, **p < 0.01, ***p < 0.001. Graphs represent mean ± SD. See also Tables S1 and S2. a role for other cytokines or surface receptors. The source of active TGF-b might be multiple cell types. Pulmonary epithelial cells might participate in tissue-specific modulation of innate immune cells (Denney et al., 2015) . However, in our studies the DC themselves, and the Treg cells induced by the DC, appeared the major contributors, consistent with the notion that DC are the main activators of latent TGF-b (Travis et al., 2007; Worthington et al., 2011) . Acquisition of tolerogenic functions by DC has also been observed following mucosal vaccination against Chlamydiae in mice (Stary et al., 2015) , suggesting that this is a general phenomenon that develops following mucosal immunity. These results complement findings that the microenvironment modulates the function of macrophages and DC in the bone-marrow during the early phase of sepsis (Askenase et al., 2015) , and that secondary mediators of inflammation, such as IFN-a and TGF-b, reduce CD4 T cells effector differentiation and enhance FoxP3 expression after resolution of sepsis (Mohammed et al., 2016; Thompson et al., 2016) . The effects we report can be considered an extension of the phenomenon of ''immunological training'' induced locally by commensal flora and other environmental stimuli (Carr et al., 2016) . This process might allow the cellular composition and function of immune cells emerging from bone marrow precursors to adapt to the specific conditions of the tissue where they will exert their function. The same adaptability may enable the mucosal immune system to adjust its threshold of responsiveness to changing levels of pathogen burden over time, due for instance to seasonal variations or change in environment (Beura et al., 2016) . The long term immunosuppression that ensues in mice or humans that survive severe infections can be considered a deleterious consequence of over-adaptation to a challenge that in normal conditions would lead to death but can be overcome in the controlled conditions of the laboratory (mice) or intensive care units (humans). In less severe infection, this adaptation might be a beneficial response to reduce inflammation, promoting healing of damaged tissue through activation of collagen synthesis by TGF-b (Roberts et al., 1986) and preventing auto-immunity against self-antigens released by injured cells (Campisi et al., 2016) . Importantly, the signals that cause local cell imprinting are non-antigen specific, explaining why recovery from a primary infection can increase the susceptibility to an entirely new pathogen. A beneficial outcome of this phenomenon might be reduced susceptibility to chronic non-infectious inflammatory diseases (Kashiwagi et al., 2015; Sabatel et al., 2017) .
We showed that circulating DC of sepsis or trauma patients express characteristic markers of mouse paralyzed DC such as a high level of Blimp1, a transcription factor associated with reduced immunogenicity (Kim et al., 2011) . The presence of Blimp1 high DC in critically ill patients might be a prognostic marker of extended immunosuppression, affording an opportunity for early intervention to prevent secondary infections in this high-risk cohort of patients. This might be achieved by reducing the exposure of the patients to potential pathogens or applying antibiotic prophylaxis . Alternatively, treatments that reduce the formation of paralyzed DC such as blockade of TGF-b activity might reduce the duration of immunosuppression. Another point of intervention might be overcoming defects in cytokine production or antigen presentation; for example, treatment with immunogenic cytokines such as IL-12 had protective effects in mice and might exert similar benefits in humans.
In conclusion, we propose that sepsis-or trauma-induced immunosuppression should be considered a consequence of local immune reprogramming rather than immune failure. Our results show that DC and probably macrophages play pivotal roles in this process and might be targeted for therapeutic intervention to prevent secondary infections as are often observed in intensive care units (Hotchkiss et al., 2013b; van Vught et al., 2016a) .
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